Umoja Biopharma announced a $100 million Series C round that will help the Seattle-based company further develop its CAR ...

A new type of cell-based immunotherapy shows promise for B-cell lymphomas, and due to innovations in manufacturing, could ...

Immunotherapy is a modern approach to cancer treatment that uses a patient's own immune system to help fight tumors. It has ...

The therapy, dubbed OST-HER2, uses a HER2-bioengineered form of the bacteria Listeria monocytogenes to trigger an immune ...

Immunotherapy is a modern approach to cancer treatment that uses a patient's own immune system to help fight tumors.

The study found that patients with muscle-invasive bladder cancer had significantly less risk of cancer progressing or ...

A phase 1 clinical trial co-led by researchers at Washington University School of Medicine in St. Louis found that a new type ...

R-5780, an oral immuno-oncology drug designed to activate gut-regulated immune pathways, will now be evaluated in a phase 1 ...

Overall survival at two years was 82.2% in the durvalumab group and 75.2% in the comparator group. Durvalumab (brand name ...

Israel Prize winner Prof. Michal Schwartz says her team's work fighting Alzheimer's can lead to treatments that boost immune ...

A major clinical trial, led by the University of Sheffield, has revealed survival rates for patients with operable bladder ...

A new study uncovers how a novel immunotherapy prevents squamous cell carcinoma, with benefits lasting five years after treatment. This therapy is the first to activate specific components of the ...